Orlando, FL -- (SBWIRE) -- 08/23/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Banco Santander (Brasil) SA(ADR)(NYSE:BSBR), Rockwell Medical Inc(NASDAQ:RMTI)'
Banco Santander (Brasil) SA(ADR)(NYSE:BSBR) shares gained 0.69% to $5.83. The company is considering acquisitions to strengthen its real estate and payroll-deductible loan portfolios, Chief Executive Jesús Zabalza told journalists on July 30. Earlier in the day, the local affiliate of Spain's Banco Santander reported a stronger-than-expected profit in the second quarter as a sharp decline in defaults allowed the bank to cut bad-loan provisions.
Should Investors Buy BSBR After Yesterday’s Slump? Find Out Here
Additionally, the company on May 13 announced that following the announcements made on February 22, 2011 and July 14, 2011, in relation to the sale of the total shares of its wholly owned subsidiary Zurich Santander Brasil Seguros e Previdencia SA (current name Santander Seguros SA) (Zurich Santander Seguros) to Zurich Santander Insurance America SL (current name of ZS Insurance America SL), a holding company located in Spain whose 51% stake is held by Zurich Financial Services Ltd and its affiliated companies and 49% by Banco Santander SA, the Company’s controlling shareholder, the total value of the transaction was of BRL 2,744,990,429.98 resulting in a price reduction of BRL 6,567,142.00.
Rockwell Medical Inc(NASDAQ:RMTI) shares dropped 1.23% to $5.60. RMTI‘s stock had its “buy” rating restated by analysts at Summer Street in a research report issued to clients and investors on August 5. They currently have a $20.00 target price on the stock.
Can Traders Buy RMTI After The Solid Rally? Get Free Trend Analysis Here
Additionally, the company on August 1 reported financial results for the second quarter of 2013. For the quarter, Rockwell reported a loss of ($11.9) million or ($0.38) per share compared to ($11.9) million or ($0.58) per share in the second quarter of 2012. The lower loss per share was due to additional shares outstanding in 2013. Non-cash charges for equity compensation were $1.6 million.
Moreover, the company on July 22 announced that its second Phase 3 efficacy study for SFP, called CRUISE-2, has completed patient dosing. The CRUISE-2 clinical study is the final Phase 3 study for Soluble Ferric Pyrophosphate (SFP), Rockwell's investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)